Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Radioimmunoguided surgery using the monoclonal antibody B72. 3 in colorectal tumors

Journal Article · · Dis. Colon Rectum; (United States)
DOI:https://doi.org/10.1007/BF02554623· OSTI ID:5726051
The authors have developed a hand-held gamma-detecting probe (GDP) for intraoperative use that improves the sensitivity of external radioimmunodetection. Radiolabeled monoclonal antibody (MAb) B72.3 was injected in six patients with primary colorectal cancer and 31 patients with recurrent colorectal cancer an average of 16 days preoperatively. The GDP localized the MAb B72.3 in 83 percent of sites. The technique, known as a radioimmunoguided surgery (RIGS) system did not alter the surgical procedure in patients with primary colorectal cancer but did alter the approach in 26 percent (8/31) of patients with recurrent colorectal cancer. Two patients avoided unnecessary liver resections and two underwent extraabdominal approaches to document their disease. The RIGS system may influence the short-term morbidity and mortality of surgery for colorectal cancer. Larger series and longer follow-up are needed to determine whether the RIGS system confers a survival advantage to the patient with colorectal cancer.
Research Organization:
Ohio State Univ., Columbus
OSTI ID:
5726051
Journal Information:
Dis. Colon Rectum; (United States), Journal Name: Dis. Colon Rectum; (United States) Vol. 30:10; ISSN DICRA
Country of Publication:
United States
Language:
English